Clinical trial
A Phase I, Randomized, Observer-blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV211 in Adult Volunteers
NCT05718037 is registered in ClinicalTrials.gov with Wuhan BravoVax Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Observer-blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV211 in Adult Volunteers
- Lead sponsor
- Wuhan BravoVax Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- August 1, 2023
- Completion date
- July 31, 2024
- Enrollment
- 40 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.